Chronic low-grade inflammation \u2014 a state that geroscience researchers call \u201cinflammaging\u201d \u2014 is one of the most thoroughly documented drivers of biological aging.
Inflammation Control: Addressing Inflammaging at the Clinical Level
Chronic low-grade inflammation \u2014 a state that geroscience researchers call \u201cinflammaging\u201d \u2014 is one of the most thoroughly documented drivers of biological aging.
Unlike the acute inflammation you feel after an injury or infection, inflammaging is silent and persistent. It produces no fever, no swelling, and no obvious symptoms. But over years and decades, it accelerates cellular aging, damages blood vessels, impairs insulin signaling, degrades cognitive function, and dramatically increases the risk of cardiovascular disease, cancer, and neurodegenerative disease.
At Advanced Vitality Group, inflammation control is a core component of our longevity programs. We use validated blood biomarkers to quantify the degree of systemic inflammation, identify its sources, and apply evidence-based interventions — physician-supervised, backed by published clinical data — to reduce it.
What Is Inflammaging?
The term “inflammaging” was coined by Italian immunologist Claudio Franceschi and colleagues to describe the chronic, low-grade pro-inflammatory state that characterizes aging. This is not an incidental feature of getting older — it is an active, biologically driven process with specific cellular sources.
The primary drivers of inflammaging include the accumulation of senescent cells, which secrete a toxic mixture of inflammatory cytokines, enzymes, and growth factors called the SASP (senescence-associated secretory phenotype). Mitochondrial dysfunction is another major contributor: damaged mitochondria release mitochondrial DNA and reactive oxygen species that activate innate immune receptors, triggering sustained inflammatory signaling. Gut microbiome dysbiosis — which increases intestinal permeability and systemic exposure to bacterial endotoxins — is increasingly recognized as a third major driver. And age-related immune dysregulation itself, including reduced regulatory T cell function and hyperactivation of innate immune pathways, perpetuates the inflammatory state.
The consequence of these converging mechanisms is a bloodstream chronically elevated in pro-inflammatory proteins — hs-CRP, IL-6, TNF-α, fibrinogen — that silently damage tissues across every organ system.
Why Inflammaging Matters: Disease Consequences
The clinical significance of chronic low-grade inflammation has been established through decades of epidemiological and interventional research. Elevated hs-CRP — one of the most accessible clinical biomarkers of systemic inflammation — independently predicts cardiovascular events at levels that most physicians would not consider clinically abnormal. A landmark series of studies by Paul Ridker and colleagues at Harvard demonstrated that individuals with hs-CRP above 3.0 mg/L had significantly higher rates of myocardial infarction and stroke, even after adjustment for LDL cholesterol (Ridker PM et al., NEJM, 1997; 2002).
IL-6, secreted primarily by adipose tissue and senescent cells, predicts all-cause mortality in population studies and is a central mediator of the metabolic deterioration associated with aging. TNF-α directly impairs insulin receptor signaling, making it a driver of both type 2 diabetes and the body composition changes typical of advancing age. Neuroinflammation — mediated by IL-1β and TNF-α in the central nervous system — is a major pathological feature of Alzheimer’s disease and other neurodegenerative conditions.
Clinical Biomarkers for Inflammation Assessment
| Biomarker | Low Risk | Elevated | Clinical Significance |
|---|---|---|---|
| hs-CRP (mg/L) | < 1.0 | > 3.0 | AHA cardiovascular risk classification; systemic inflammaging marker |
| IL-6 (pg/mL) | < 3.0 | > 6.0 | SASP component; senescent cell burden; all-cause mortality predictor |
| TNF-α (pg/mL) | < 8.0 | > 15.0 | Insulin signaling impairment; metabolic syndrome driver |
| Homocysteine (μmol/L) | < 10 | > 15 | Endothelial injury; cardiovascular and cognitive risk |
| Fibrinogen (mg/dL) | < 300 | > 400 | Acute phase reactant; coagulation risk; cardiovascular marker |
Reference: Ridker PM. “Clinical application of C-reactive protein for cardiovascular disease detection and prevention.” Circulation. 2003; and AHA/CDC Scientific Statement on CRP.
Evidence-Based Interventions for Inflammation Control
Omega-3 Fatty Acids
Long-chain omega-3 fatty acids — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — are among the most extensively studied anti-inflammatory interventions in clinical medicine. A meta-analysis of 68 randomized controlled trials found that omega-3 supplementation significantly reduced circulating CRP, IL-6, and TNF-α (Calder PC et al., Nutrients, 2017). The REDUCE-IT trial — a large, multicenter RCT published in the New England Journal of Medicine in 2019 — demonstrated that high-dose icosapentaenoic acid (4 g/day as prescription Vascepa) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides, with anti-inflammatory effects contributing to this benefit (Bhatt DL et al., NEJM, 2019).
In clinical practice, the omega-3 index — the percentage of EPA and DHA in red blood cell membranes — is the preferred biomarker. A target above 8% is associated with lowest cardiovascular risk. We recommend 2–4 g per day of combined EPA and DHA under physician supervision.
Exercise
Physical activity reduces systemic inflammation through multiple mechanisms: reduction of visceral adipose tissue (a major cytokine producer), increased secretion of anti-inflammatory myokines including IL-10 and IL-13, improved insulin sensitivity, and autophagy activation. A meta-analysis of 35 randomized controlled trials confirmed that regular exercise significantly reduced hs-CRP and IL-6 in adults, with both aerobic and resistance training producing measurable effects (Fedewa MV et al., Journal of Science and Medicine in Sport, 2021). The combination of both modalities produces the strongest anti-inflammatory outcomes.
Mediterranean Dietary Pattern
The Mediterranean diet — characterized by high intake of vegetables, fruits, legumes, whole grains, and olive oil, with moderate fish consumption and limited processed foods — has the most robust dietary evidence for anti-inflammatory effects. A meta-analysis of 18 randomized trials found that Mediterranean diet adherence significantly reduced hs-CRP by an average of 0.58 mg/L and IL-6, with effects comparable in magnitude to low-dose pharmacological intervention (Schwingshackl L et al., Nutrients, 2014).
Senolytic Therapy: Removing the Source
Because senescent cells are a primary cellular source of SASP-driven inflammation, eliminating them with senolytic agents addresses the root cause rather than the downstream markers. Clinical trials of dasatinib plus quercetin (D+Q) have demonstrated reductions in circulating SASP factors including IL-6, MMP-2, and MMP-9, alongside improvements in physical function in patients with fibrotic and age-related disease. We discuss senolytic protocols on an individualized basis where the current evidence supports their use.
Low-Dose Colchicine
The LoDoCo2 trial — a randomized, placebo-controlled trial of 5,522 patients published in the New England Journal of Medicine in 2020 — demonstrated that low-dose colchicine (0.5 mg per day) significantly reduced major cardiovascular events in patients with stable coronary artery disease (Nidorf SM et al., NEJM, 2020). The mechanism is inhibition of the NLRP3 inflammasome — a key driver of chronic vascular inflammation. This positions low-dose colchicine as a clinically evidence-supported anti-inflammatory option for patients with documented cardiovascular risk and elevated inflammation, considered on an individualized basis.
Frequently Asked Questions
Scientific References
- Franceschi C, et al. "Inflammaging and anti-inflammaging." Annals of the New York Academy of Sciences. 2007;1100:244–252.
- Ridker PM, et al. "Inflammation, aspirin, and cardiovascular risk." NEJM. 1997;336(14):973–979.
- Bhatt DL, et al. "Cardiovascular risk reduction with icosapentaenoic acid (REDUCE-IT)." NEJM. 2019;380(1):11–22.
- Nidorf SM, et al. "Colchicine in patients with chronic coronary disease (LoDoCo2)." NEJM. 2020;383:1838–1847.
- Fedewa MV, et al. "Exercise and inflammation." Journal of Science and Medicine in Sport. 2021;24(8):795–802.
- Schwingshackl L, Hoffmann G. "Mediterranean dietary pattern and inflammation." Nutrients. 2014.
- Calder PC, et al. "Omega-3 fatty acids and inflammatory biomarkers." Nutrients. 2017.
- Donath MY, Shoelson SE. "Type 2 diabetes as an inflammatory disease." Nature Reviews Immunology. 2011;11(2):98–107.
Take Control of Chronic Inflammation
Schedule a consultation to measure your inflammatory biomarkers and design a targeted intervention plan.